Analysis and identify of gene associated with EGFR mutation by gene chip for SNPs

点击翻译按钮获取中文摘要

Lung cancer is a major cause of cancer death, and one of the most resistant cancers to treatment. Several mutations in the lung tumor were found in female, non-smoker patients with adenocarcinoma. These mutations were associated with not only oncogenicity but the target of therapy. Gefitinib is an orally administered tyrosine kinase inhibitor(TKI) of EGFR that was approved in Japan for the first time in the world. This drug has substantial role on treatment with non-small cell lung cancer patients who have characteristics that include female, never smoker, and adenocarcinoma histology. The response of treatment with gefitinib was found strongly correlated with both these patient characteristics and EGFR mutations. In addition, it was reported that there are more frequent EGFR mutations in Asian patients than in Westerners. On the hypothesis of that there are some genes associated with this ethnic difference in incidence of mutation, we conducted the study to identify these associated genes by the analysis of SNP through the whole genome with Gene chip assay.Result : We collected blood samples from 64 patients with EGFR mutation and extracted DNA and analyzed whole genome SNP with SNP Array 6.0 which defined SNPs in more than 900, 000 sites. We found two sites associated with EGFR activating mutation with this method. We are planning to conduct re-examination with other sample set.